Case Study

Only available on StudyMode
  • Topic: Pleading, Thousand Oaks, California, Ethics
  • Pages : 2 (468 words )
  • Download(s) : 403
  • Published : January 17, 2013
Open Document
Text Preview
Case Study
Complete Case: Amgen Whistleblowing
Read and write up an executive summary on the case, including answers to the following questions. 1. How did Amgen's unethical behavior contribute to the problems with Medicaid kickbacks? 2. Why does the public consider this scandal to have an unethical dilemma? 3. Explain what is meant by whistleblowing?

Include your opinions and identify any gaps between public expectations of ethical standards and universal professional codes of ethical standards. Case : Amgen Whistleblowing Case

Amgen, a Thousand Oaks, California–based company, had the unenviable task of dealing with lawsuits filed by 15 states in 2009 alleging a Medicaid kickback scheme.1 To make matters worse, two additional whistleblowing lawsuits were filed against the company in Ventura County. The complaints, which don't appear related to the fraud alleged by the group of states, were brought by former employees who said they had uncovered wrongdoing at the biotech giant and were terminated after they raised red flags to superiors. One employee alleged the company violated federal law by under-reporting complaints and problems with the company's drugs after they hit the market. The facts of that lawsuit are described below.

Former Amgen employee Shawn O'Brien sued Amgen for wrongful termination on October 9, 2009, alleging he was laid off in October 2007 in retaliation for raising concerns about how the company reported complaints and problems with drugs already on the market. O'Brien worked as a senior project manager for Amgen's “Ongoing Change Program,” according to the lawsuit filed in Ventura County Superior Court. His job was to improve Amgen's “compliance processes with high inherent risk to public safety, major criminal and civil liability, or both,” according to the lawsuit. The lawsuit alleged that in April 2007, Amgen's board of directors flagged the company's process for dealing with post-market complaints about drugs as a...